Retroperitoneal Lymph Node Metastasis in Gallbladder Cancer: As Bad as Distant Metastasis

Nalini Kanta Ghosh1 Rahul 1 Ashish Singh1 Supriya Sharma1 Ashok Kumar1 Rajneesh Kumar Singh1 Anu Behari1 Ashok Kumar1 Vinay Kumar Kapoor1 Rajan Saxena1

1 Department of Surgical Gastroenterology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

South Asian J Cancer

Abstract

Background  Regarding gallbladder cancer (GBC) there is conflicting evidence in the literature whether retroperitoneal lymph nodal metastases (RLNM) should be considered as regional nodal metastasis or as distant metastasis (DM) and the jury is out on radical curative surgery in presence of RLNM. This is an analysis of GBC patients, to see the effect of RLNM on survival and to compare with that of patients with DMs.

Methods  A retrospective analysis of a prospective database of patients of GBC with RLNM (interaortocaval and paraaortic) or DM on frozen section biopsy at surgery, between January 2013 and December 2018. Data was analyzed using the Statistical Package for the Social Sciences software (version 22.0). Survival in these two groups (RLNM and DM) was compared with log-rank test. A p-value of < 0.05 was considered significant.

Results  A total of 235 patients with ostensibly resectable GBC underwent surgical exploration. The planned curative resection was abandoned in 91 (39%) patients because of RLNM (n = 20, 9%) or DM (n = 71, 30%) on frozen section biopsy. Demographic profile and blood parameters were similar. The median survival for RLNM and DM groups were 5 (range 2–26) and 6 (range 2–24) months, respectively, with no significant difference on log-rank test (p = 0.64). There was no 3-year or longer survivor in either group.

Conclusion  Due to similar poor survival in presence of RLNM or DM, RLNM should be considered as the equivalent of DM. This study strengthens evidence to avoid curative surgery in patients with RLNM. These lymph nodes should be sampled preoperatively, if suspicious on imaging, for fine-needle aspiration cytology and at surgery, as a routine for frozen section histological examination before initiating curative resection to avert a futile exercise.

Keywords
► gallbladder cancer
► retroperitoneal lymph node metastasis
► interaortocaval lymph node metastasis
► para-aortic lymph node metastasis
► distant metastasis

How to cite this article: Ghosh NK, R, Singh A, et al. Retroperitoneal Lymph Node Metastasis in Gallbladder Cancer: As Bad as Distant Metastasis South Asian J Cancer 2022;00(00):00–00.


© 2022. MedIntel Services Pvt Ltd. All rights reserved.
This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Introduction

In gallbladder cancer (GBC), there is conflicting evidence in the literature whether retroperitoneal lymph nodal metastases (RLNM) should be considered as regional nodal metastases or as distant metastases (DMs) and the jury is out on radical curative surgery in presence of RLNM. This is an analysis of GBC patients, to see the effect of RLNM on survival and to compare with that of patients with DMs, where curative surgery was abandoned due to RLNM or DM, found intraoperatively.

Material and Methods

This study was performed at the department of surgical gastroenterology at a tertiary care center in North India where GBC is rife. All patients of GBC, where curative resection was abandoned between January 2013 and December 2018, on account of positive retroperitoneal lymph node (RLN) or DM on frozen section biopsy, were studied for survival. The study design is depicted in Fig 1.

All patients were staged with a triple-phase computed tomography (CT) scan. In case of locally advanced disease where major hepatectomy or hepaticopancreaticoduodenectomy was contemplated, neoadjuvant treatment was instituted after a staging laparoscopy (SL). Patients with obstructive jaundice underwent preoperative or preneoadjuvant treatment biliary drainage. Those who were nonmetastatic and possibly resectable on imaging were considered for curative surgery. Most of the patients underwent SL. In case a liver, peritoneal, or omental nodule was seen on SL, the lesion was biopsied and sent for frozen section examination. In the absence of dissemination (liver, peritoneal, omental nodule, or ascites) on SL, the findings were confirmed at laparotomy when the RLNs were sampled for frozen section biopsy. The planned curative resection was abandoned if the biopsy report suggested metastatic disease and the patients were offered palliative care. The study population was divided into two groups based on the site of metastatic disease—RLNM and DM, and outcome was compared. Demographic profile, preoperative blood parameters, neoadjuvant treatment, biliary drainage, and postoperative palliative treatment were recorded. Survival was calculated from the day of surgery. Patients were followed up through hospital visits and telephonically.

Data was analyzed using the Statistical Package for the Social Sciences software (version 22.0). Continuous variables were compared with independent t-test and categorical variables were compared with chi-square test. A p-value of <0.05 was considered significant. In case of skewed variables, that is, bilirubin and survival, median and
interquartile range (IQR) were used. Survival among both the groups (RLNM and DM) was compared with log-rank test.

**Results**

A total of 235 patients with ostensibly resectable GBC underwent surgical exploration between January 2013 and December 2018. The planned curative resection was executed in 144 (61%) patients and abandoned in 91 (39%) patients because of RLNM (n = 20, 9%) or DM (n = 71, 30%) on frozen section biopsy. Demographic profile including age, gender, comorbidities, preoperative clinical features, blood parameters (hemoglobin, bilirubin, albumin, and international normalized ratio), requirement of biliary drainage, or neo-adjuvant treatment were comparable between the two groups as shown in **Table 1**. SL was performed in 214 out of 235 patients (21 patients underwent laparotomy without SL for techno-logistical reasons). In the 71 patients, where the curative resection was aborted, metastases were detected on laparoscopy in 54 patients and at laparotomy in 17 patients (15 of these were missed at SL, while 2 were found in patients who did not undergo a prelaparotomy SL).

Metastases missed at laparoscopy were peritoneal (n = 6), omental (n = 5), liver (n = 3), and gastric serosal nodule (n = 1). Overall, SL changed the management in 54/214 (25%) patients by averting a laparotomy and abandoning curative resection. The RLNM included interaortocaval nodes (n = 18) and paraaortic nodes (n = 2) in patients without any DM. The DM group consisted of liver nodules (n = 27), peritoneal nodules (n = 34), omental metastasis (n = 15), and malignant ascites on fluid cytology (n = 1). Six patients had polymetastatic disease.

Note that 50% patients in the RLNM group received palliative treatment as compared with 22% in the DM group; the difference was statistically significant (p = 0.04). In majority of the cases, the patients opted against chemotherapy either due to logistic issues or the nihilism associated with disseminated disease. All patients were followed up. The median survival for RLNM and DM groups were 5 months (range 2–26; IQR 3–11) and 6 months (range 2–24; IQR 4–10), respectively, without any significant difference on log-rank test (p-value = 0.64) (►Fig. 2).

There was no 3-year survivor in either group. In the studied population, only one patient with liver metastasis

<table>
<thead>
<tr>
<th>Parameters</th>
<th>RLNM (n = 20)</th>
<th>DM (n = 71)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years, mean ± SD [range]</td>
<td>53.6 ± 8.5 [35–71]</td>
<td>51.2 ± 10.8 [30–80]</td>
<td>0.14</td>
</tr>
<tr>
<td>Sex, M:F</td>
<td>7:13</td>
<td>26:45</td>
<td>1.0</td>
</tr>
<tr>
<td>BMI in kg/m², mean ± SD [range]</td>
<td>23.5 ± 3.9 [17.7–32.3]</td>
<td>22.4 ± 3.6 [18.5–40.2]</td>
<td>0.29</td>
</tr>
<tr>
<td>Comorbidity, n (%)</td>
<td>8 (40)</td>
<td>20 (28.1)</td>
<td>0.14</td>
</tr>
<tr>
<td>Diabetes, n (%)</td>
<td>6 (30)</td>
<td>9 (12.6)</td>
<td>0.08</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>4 (20)</td>
<td>10 (14)</td>
<td>0.5</td>
</tr>
<tr>
<td>Coronary artery disease (CAD), n (%)</td>
<td>0</td>
<td>3 (4.2)</td>
<td>1.0</td>
</tr>
<tr>
<td>Jaundice, n (%)</td>
<td>4 (20)</td>
<td>20 (28.1)</td>
<td>0.57</td>
</tr>
<tr>
<td>LOA, n (%)</td>
<td>11 (55)</td>
<td>38 (53.5)</td>
<td>0.55</td>
</tr>
<tr>
<td>LOW, n (%)</td>
<td>11 (55)</td>
<td>39 (54.9)</td>
<td>1.0</td>
</tr>
<tr>
<td>Incidental, n (%)</td>
<td>1 (5)</td>
<td>12 (16.9)</td>
<td>0.28</td>
</tr>
<tr>
<td>Node involvement (N +) on preoperative images (CECT/USG), n (%)</td>
<td>17 (85)</td>
<td>52 (73.2)</td>
<td>0.38</td>
</tr>
<tr>
<td>Hemoglobin in g/dL mean ± SD</td>
<td>11.3 ± 1.4</td>
<td>11.5 ± 1.8</td>
<td>0.29</td>
</tr>
<tr>
<td>Bilirubin in g/dL median (IQR)</td>
<td>0.8 (0.45–1.4)</td>
<td>0.8 (0.5–1.5)</td>
<td>0.07</td>
</tr>
<tr>
<td>Albumin in g/dL mean ± SD</td>
<td>3.9 ± 0.57</td>
<td>3.9 ± 0.51</td>
<td>0.6</td>
</tr>
<tr>
<td>INR mean ± SD</td>
<td>1.01 ± 0.13</td>
<td>1.03 ± 0.11</td>
<td>0.74</td>
</tr>
<tr>
<td>Preoperative biliary drainage, n (%)</td>
<td>4 (20)</td>
<td>11 (15.4)</td>
<td>0.73</td>
</tr>
<tr>
<td>Neoadjuvant treatment, n (%)</td>
<td>2 (10)</td>
<td>3 (4.2)</td>
<td>0.3</td>
</tr>
<tr>
<td>Palliative treatment, n (%)</td>
<td>10 (50)</td>
<td>16 (22.5)</td>
<td>0.04</td>
</tr>
<tr>
<td>Survival in months median (IQR) [range]</td>
<td>5 (3–11) [2–26]</td>
<td>6 (4–10) [2–24]</td>
<td>0.08</td>
</tr>
<tr>
<td>Six-month survival, n (%)</td>
<td>9 (45)</td>
<td>37 (52.1)</td>
<td>0.62</td>
</tr>
<tr>
<td>1-year survival, n (%)</td>
<td>4 (20)</td>
<td>13 (18.3)</td>
<td>1.0</td>
</tr>
<tr>
<td>2-year survival, n (%)</td>
<td>2 (10)</td>
<td>1 (1.4)</td>
<td>0.12</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; CECT, contrast-enhanced computed tomography; INR, international normalized ratio; IQR, interquartile range; LOA, loss of appetite; LOW, loss of weight; SD, standard deviation; USG, ultrasonography.
and stable disease is still alive (18 months postsurgery), with no evidence of disease progression after 6 cycles of chemotherapy.

When survival was compared between the RLNM and DM groups receiving palliative chemotherapy, there was no significant survival difference (median 11 months in both the groups and on log-rank test p-value = 0.89) (►Fig. 3).

Discussion

GBC is the most common malignancy in the biliary tract. In GBC lymph node involvement is associated with poor survival.2–4 The extent of lymphadenectomy and the level of lymph node involvement which precludes curative surgery is still a matter of controversy. A study by Murakami et al on the survival of patients with paraaortic lymph node (n = 17) metastasis in resected biliary carcinoma documented absence of any survival advantage.5 Similarly, other authors have also documented poor outcomes in the presence of RLNM in GBC akin to DM.3,4,6–9 On the contrary, Nishio et al have shown that in presence of RLN involvement, the survival is better after resection than nonoperated similar patients with RLNM (p-value 0.014).10 There are also few case reports showing anecdotal long-term survival in the presence of distant lymph node metastasis.11,12 To the best of our knowledge, this report is the largest reported experience on survival of GBC patients with RLNM. In this population, there was no significant difference in survival among both the groups indicating that the prognosis of the RLNM group was as poor as of the DM group. All patients were counseled about the disease stage and prognosis and they were offered palliative chemotherapy. In the subgroup of patients receiving palliative chemotherapy again the survival was similar for patients with RLNM or DM. Our study validates poor prognosis of the RLNM, as with the DM groups.

Because of poor prognosis, RLNM should actively be sought for in the preoperative imaging, so as to avoid unnecessary laparotomy. Presently, imaging modalities are less accurate in evaluation of RLNM unless the nodes are large in size with obvious signs of involvement. CT criteria for evaluation for metastatic lymph node have been found to have poor sensitivity (14.7%) and positive predictive value (33.3%).14 Similarly, positron emission tomography scan also has limited role.15 If an enlarged RLN is

Fig. 2 Comparison of survival between retroperitoneal lymph node metastasis (RLNM) and distant metastasis (DM) groups.
suspected to be involved at imaging, it should be target for fine-needle aspiration cytology (FNAC) under ultrasound, CT, or endoscopic ultrasound guidance. But the preoperative sampling has limitations because of difficult location and sampling error leading to a false negative rate of almost 30%. Hence, in all cases of GBC, retroperitoneal (interaortocaval and paraaortic) lymph nodes should be sampled as a routine for frozen section histological examination before starting the curative resection to avert a futile extensive surgery.

**Conclusion**

GBC patients with RLNM have poor survival similar to DMs and should be considered as the equivalent of DM. This study strengthens evidence to avoid curative resectional surgery in patients with RLNM. These lymph nodes should be sampled, preoperatively if suspicious on imaging for FNAC and at surgery, as a routine for frozen section histological examination before initiating curative resection to avert a futile exercise.

**Authors’ Contributions**

Conception and design: A.S., N.K.G., R.S., V.K.K.
Administrative support: V.K.K., R.S.
Provision of study materials or patients: R.S., V.K.K.
Collection and assembly of data: All authors.
Manuscript writing: All authors.
Final approval of manuscript: All authors.

**Ethical Statement**

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Ethical Approval**

It was a retrospective analysis of prospective database so no ethical clearance was sought.

**Funding**

No funds procured for this study.

---

**Fig. 3** Survival comparison among retroperitoneal lymph node metastasis (RLNM) and distant metastasis (DM) groups who received palliative chemotherapy.
Conflict of Interest
All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.

References